Shoulder Innovations Inc

The stock remains in a high-confidence Stage 2 uptrend following a clear breakout and continuation patterns, supported by rising EMAs and expanding volume. However, short-term conditions are extended and overbought, suggesting deferred entry until a healthier pullback into the 9/21 EMA support zone.

• ↑Q1 2026 revenue of $16.7M (+65% YoY); full-year guide $65–68M (+37–44%)
• ↑Sole public pure-play in $2.8B shoulder arthroplasty market, supporting niche moat
• ↓Q1 net loss of $8.4M vs $4.7M prior year; SG&A at $18.2M due to headcount and public costs